Therefore, SMTNL1 may be a feasible therapeutic target for progesterone-dependent inhibition of endometrial epithelial cells during hyperglycemia and insulin-sensitizing endometrium in gestational diabetes or other metabolic disorders. The gene discussed is SMTNL1; the disease is metabolic disease.